Cerevel Therapeutics is a biopharmaceutical company working relentlessly to unravel the mysteries of the brain to treat neuroscience diseases.
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $125M
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
| - | Ally Bridg... | ally-bridg... |
| - | Bain Capit... | baincapita... |
| 28.05.2024 | Bain Capit... | baincapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.04.2021 | - | $125M | - |
Mentions in press and media 11
| Date | Title | Description |
| 07.10.2024 | Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For Obesity | Kailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million... |
| 11.10.2023 | Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock | - |
| 13.12.2021 | PHYSICIAN AND SCIENTIST, SERGE PRZEDBORSKI, JOINS LUCIOLE PHARMACEUTICALS' SCIENCE ADVISORY BOARD | NATICK, Mass., Dec. 13, 2021 /PRNewswire/ -- Luciole Pharmaceuticals, Inc is pleased to announce that Serge Przedborski, MD, Ph.D., is joining the company's scientific advisory board. Dr. Przedborski, is the Page and William Black Professor... |
| 02.07.2021 | Cerevel Therapeutics : Announces Pricing of $350 Million Public Offering of Common Stock (Form 8-K) | Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock CAMBRIDGE, Mass., July 1, 2021 (GLOBE NEWSWIRE) - Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to tr... |
| 02.07.2021 | Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock | CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced un... |
| 13.04.2021 | Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon | Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinson’s disease through planned NDA submission Data readouts from tavapadon Phase 3 TEMPO program expected beginning i... |
| 13.04.2021 | CEREVEL THERAPEUTICS HOLDINGS, INC. Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon | Cerevel Therapeutics, announced an up to $125 million non-dilutive financing transaction with NovaQuest and Bain Capital to fund the full Phase 3 development program for tavapadon in Parkinsons disease, also known as the TEMPO trials. $125... |
| 15.10.2020 | It’s Raining Biotech SPACs! | SPACs are all the rage today. With the IPO market booming and public investors seeking better returns, blank check companies called “Special Purpose Acquisition Companies” (SPACs) have been fueling up their tanks and chasing down their merg... |
| 04.11.2019 | Cerevel Therapeutics Appoints Gabrielle Sulzberger to Board | BOSTON–(BUSINESS WIRE)–Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has added Gabrielle Sulzberger to serve as an independent member of its Board ... |
| - | Google Cloud launches A.I.-powered tools to accelerate drug discovery, precision medicine | Google Cloud launched two new AI-powered solutions that aim to help biotech and pharmaceutical companies accelerate drug discovery and advance precision medicine. The two suites mark Google’s latest advancements in the red-hot AI arms race.... |
Show more